SHBG

SHBG Promoter Variant — The Hormone Bioavailability Regulator

The SHBG gene on chromosome 17 encodes sex hormone-binding globulin | a liver-produced transport
protein that binds testosterone and estradiol in circulation.
Only 1-2% of testosterone and estradiol circulate as "free" bioactive hormones — the rest is bound
to SHBG (44%) or albumin (54%). By controlling how much hormone is bound versus free, SHBG acts as
a master regulator of sex hormone activity throughout the body. The rs1799941 variant sits in the
promoter region just upstream of the SHBG gene and directly influences how much SHBG protein the
liver produces. This variant is particularly important because low SHBG levels are strongly
associated with metabolic syndrome, type 2 diabetes, PCOS, and cardiovascular risk,
while genetically higher SHBG levels may protect against these conditions — though with some
unexpected trade-offs.

The Mechanism

Rs1799941 is a G-to-A polymorphism located in the regulatory promoter region of the SHBG gene on
chromosome 17p12-p13. The proximal promoter of SHBG
contains binding sites for hepatocyte nuclear factor 4-alpha (HNF4A), which activates SHBG
transcription. The A allele appears to enhance promoter activity,
leading to increased SHBG production by liver hepatocytes. In population studies, each copy of the
A allele increases serum SHBG levels by approximately 7-12 nmol/L,
with AA homozygotes showing 15-25% higher SHBG than GG homozygotes. Because SHBG binds testosterone
with 5-fold higher affinity than estradiol, changes in SHBG levels disproportionately affect
testosterone bioavailability — more SHBG means more testosterone gets locked up, reducing free
testosterone even when total testosterone remains normal.

The Evidence

The largest study of rs1799941 is the Tromsø Study, which genotyped 5,309 Norwegian men and
followed them for cardiovascular events, diabetes, cancer, and mortality.
Men with the AA genotype had 14.7% higher total testosterone and 24.7% higher SHBG compared to GG
homozygotes, but crucially, free testosterone levels did not differ significantly between genotypes.
The SNP was not significantly associated with myocardial infarction, type 2 diabetes, cancer, or
mortality, suggesting that the A allele's protective effects on SHBG may be offset by reduced free
testosterone bioavailability.

A pediatric metabolic syndrome study in Turkish children found the opposite direction of effect —
having at least one A allele associated with a 3-fold increased odds of metabolic syndrome
(OR=3.09, p=0.006). Paradoxically, in control subjects the A allele increased SHBG levels (as
expected), but in metabolic syndrome cases there was no association between genotype and SHBG,
suggesting the mechanism through which rs1799941 affects SHBG is disrupted in metabolic disease.

A study of 212 young obese males investigated rs1799941 and hypogonadism risk.
The A allele was associated with higher SHBG (AA genotype showed +12.45 nmol/L) but lower free
testosterone (AA showed -18.52 pg/mL reduction). Importantly, the A allele increased the risk of
presenting hypogonadism compared to normal free testosterone hypogonadism (OR=2.54). This reveals
the double-edged nature of the variant — higher SHBG is generally metabolically protective, but if
SHBG rises too high, it can reduce free testosterone to levels that trigger hypogonadal symptoms,
especially in obese individuals.

In 558 women with polycystic ovary syndrome (PCOS), rs1799941 genotype was independently
associated with SHBG levels after controlling for BMI, insulin resistance, and hyperandrogenism.
However, the SNP was not associated with PCOS status itself, suggesting it influences SHBG levels
but doesn't directly cause PCOS. This is consistent with the understanding that PCOS is driven more
by hyperinsulinemia and hyperandrogenism than by SHBG genetics.

Practical Implications

For carriers of the AA genotype, higher baseline SHBG production is generally protective against
metabolic syndrome and insulin resistance. However, this comes with caveats. In obesity, the AA
genotype may paradoxically increase hypogonadism risk by binding too much testosterone, leaving
insufficient free testosterone for biological action. For women with PCOS, the variant influences
SHBG levels but doesn't override the strong suppressive effects of hyperinsulinemia on SHBG — insulin
resistance will drive SHBG down regardless of genotype. The GG genotype produces less SHBG
baseline, which in lean individuals may optimize free testosterone availability, but in metabolic
syndrome states this lower SHBG exacerbates the condition by allowing more free androgens to drive
insulin resistance.

From a clinical standpoint, rs1799941 genotype helps explain why some individuals have relatively
high or low SHBG despite similar metabolic profiles. AA individuals may benefit from monitoring
free testosterone rather than total testosterone,
particularly if obese, as their high SHBG can mask functional hypogonadism. GG individuals with low
SHBG should be screened more aggressively for metabolic syndrome markers — fasting insulin, glucose,
triglycerides, and waist circumference — as they are at higher baseline metabolic risk.

Interactions

Rs1799941 frequently interacts with other SHBG gene variants, particularly rs727428 and rs6259
(Asp327Asn), which also independently influence SHBG levels. Rs727428 and rs1799941 together
account for significant variance in SHBG levels in PCOS women,
with compound effects observed when both variants are present. Additionally, the (TAAAA)n
pentanucleotide repeat polymorphism in the SHBG promoter modulates the strength of rs1799941's
effect — shorter repeats enhance promoter activity, amplifying the A allele's SHBG-raising effect.
Beyond the SHBG gene, this variant's effects are modified by metabolic state — obesity, insulin
resistance, and hepatic steatosis all suppress SHBG production through downregulation of HNF4A,
potentially overwhelming the genetic effect of rs1799941. Thus, lifestyle factors (weight,
exercise, diet) and metabolic health status significantly modulate the penetrance of this variant.